Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan

Gianni Allais, Giancarlo Acuto, Chiara Benedetto, Giovanni D'Andrea, Licia Grazzi, Gian Camillo Manzoni, Franca Moschiano, Florindo D'Onofrio, Fabio Valguarnera, Gennaro Bussone

Research output: Contribution to journalArticle

Abstract

In addition to headache, migraine is characterized by a series of symptoms that negatively affects the quality of life of patients. Generally, these are represented by nausea, vomiting, photophobia, phonophobia and osmophobia, with a cumulative percentage of the onset in about 90% of the patients. From this point of view, menstrually related migraine-a particularly difficult-to-treat form of primary headache-is no different from other forms of migraine. Symptomatic treatment should therefore be evaluated not only in terms of headache relief, but also by considering its effect on these migraine-associated symptoms (MAS). Starting from the data collected in a recently completed multicentre, randomized, double-blind, placebo-controlled, cross-over study with almotriptan in menstrually related migraine, an analysis of the effect of this drug on the evolution of MAS was performed. Data suggest that almotriptan shows excellent efficacy on MAS in comparison to the placebo, with a significant reduction in the percentages of suffering patients over a 2-h period of time.

Original languageEnglish
JournalNeurological Sciences
Volume31
Issue numberSUPPL.1
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Migraine Disorders
Therapeutics
Headache
Hyperacusis
Placebos
Photophobia
almotriptan
Cross-Over Studies
Nausea
Vomiting
Quality of Life
Pharmaceutical Preparations

Keywords

  • Acute treatment
  • Almotriptan
  • Menstrual migraine
  • Migraine-associated symptoms

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology
  • Medicine(all)

Cite this

Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan. / Allais, Gianni; Acuto, Giancarlo; Benedetto, Chiara; D'Andrea, Giovanni; Grazzi, Licia; Manzoni, Gian Camillo; Moschiano, Franca; D'Onofrio, Florindo; Valguarnera, Fabio; Bussone, Gennaro.

In: Neurological Sciences, Vol. 31, No. SUPPL.1, 06.2010.

Research output: Contribution to journalArticle

Allais, G, Acuto, G, Benedetto, C, D'Andrea, G, Grazzi, L, Manzoni, GC, Moschiano, F, D'Onofrio, F, Valguarnera, F & Bussone, G 2010, 'Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan', Neurological Sciences, vol. 31, no. SUPPL.1. https://doi.org/10.1007/s10072-010-0302-9
Allais, Gianni ; Acuto, Giancarlo ; Benedetto, Chiara ; D'Andrea, Giovanni ; Grazzi, Licia ; Manzoni, Gian Camillo ; Moschiano, Franca ; D'Onofrio, Florindo ; Valguarnera, Fabio ; Bussone, Gennaro. / Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan. In: Neurological Sciences. 2010 ; Vol. 31, No. SUPPL.1.
@article{df25c4afb97c4f59bf0371ddfdbda910,
title = "Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan",
abstract = "In addition to headache, migraine is characterized by a series of symptoms that negatively affects the quality of life of patients. Generally, these are represented by nausea, vomiting, photophobia, phonophobia and osmophobia, with a cumulative percentage of the onset in about 90{\%} of the patients. From this point of view, menstrually related migraine-a particularly difficult-to-treat form of primary headache-is no different from other forms of migraine. Symptomatic treatment should therefore be evaluated not only in terms of headache relief, but also by considering its effect on these migraine-associated symptoms (MAS). Starting from the data collected in a recently completed multicentre, randomized, double-blind, placebo-controlled, cross-over study with almotriptan in menstrually related migraine, an analysis of the effect of this drug on the evolution of MAS was performed. Data suggest that almotriptan shows excellent efficacy on MAS in comparison to the placebo, with a significant reduction in the percentages of suffering patients over a 2-h period of time.",
keywords = "Acute treatment, Almotriptan, Menstrual migraine, Migraine-associated symptoms",
author = "Gianni Allais and Giancarlo Acuto and Chiara Benedetto and Giovanni D'Andrea and Licia Grazzi and Manzoni, {Gian Camillo} and Franca Moschiano and Florindo D'Onofrio and Fabio Valguarnera and Gennaro Bussone",
year = "2010",
month = "6",
doi = "10.1007/s10072-010-0302-9",
language = "English",
volume = "31",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL.1",

}

TY - JOUR

T1 - Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan

AU - Allais, Gianni

AU - Acuto, Giancarlo

AU - Benedetto, Chiara

AU - D'Andrea, Giovanni

AU - Grazzi, Licia

AU - Manzoni, Gian Camillo

AU - Moschiano, Franca

AU - D'Onofrio, Florindo

AU - Valguarnera, Fabio

AU - Bussone, Gennaro

PY - 2010/6

Y1 - 2010/6

N2 - In addition to headache, migraine is characterized by a series of symptoms that negatively affects the quality of life of patients. Generally, these are represented by nausea, vomiting, photophobia, phonophobia and osmophobia, with a cumulative percentage of the onset in about 90% of the patients. From this point of view, menstrually related migraine-a particularly difficult-to-treat form of primary headache-is no different from other forms of migraine. Symptomatic treatment should therefore be evaluated not only in terms of headache relief, but also by considering its effect on these migraine-associated symptoms (MAS). Starting from the data collected in a recently completed multicentre, randomized, double-blind, placebo-controlled, cross-over study with almotriptan in menstrually related migraine, an analysis of the effect of this drug on the evolution of MAS was performed. Data suggest that almotriptan shows excellent efficacy on MAS in comparison to the placebo, with a significant reduction in the percentages of suffering patients over a 2-h period of time.

AB - In addition to headache, migraine is characterized by a series of symptoms that negatively affects the quality of life of patients. Generally, these are represented by nausea, vomiting, photophobia, phonophobia and osmophobia, with a cumulative percentage of the onset in about 90% of the patients. From this point of view, menstrually related migraine-a particularly difficult-to-treat form of primary headache-is no different from other forms of migraine. Symptomatic treatment should therefore be evaluated not only in terms of headache relief, but also by considering its effect on these migraine-associated symptoms (MAS). Starting from the data collected in a recently completed multicentre, randomized, double-blind, placebo-controlled, cross-over study with almotriptan in menstrually related migraine, an analysis of the effect of this drug on the evolution of MAS was performed. Data suggest that almotriptan shows excellent efficacy on MAS in comparison to the placebo, with a significant reduction in the percentages of suffering patients over a 2-h period of time.

KW - Acute treatment

KW - Almotriptan

KW - Menstrual migraine

KW - Migraine-associated symptoms

UR - http://www.scopus.com/inward/record.url?scp=77955886102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955886102&partnerID=8YFLogxK

U2 - 10.1007/s10072-010-0302-9

DO - 10.1007/s10072-010-0302-9

M3 - Article

C2 - 20464599

AN - SCOPUS:77955886102

VL - 31

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL.1

ER -